Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company focused on hematopoietic stem cell therapy, targeting improvement in outcomes for patients with severe diseases like sickle cell disease and specific blood cancers. The firm utilizes cutting-edge technologies to reduce transplant-related complications, addressing significant unmet needs within the hematology sector. With a strong intellectual property portfolio and key strategic partnerships, Jasper is well-positioned to advance its clinical pipeline, reflecting its dedication to innovative solutions in regenerative medicine.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-69.94M |
| Operating Margin | 0.00% |
| Return on Equity | -244.20% |
| Return on Assets | -112.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.12 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $28.01M |
| Float | $21.97M |
| % Insiders | 1.19% |
| % Institutions | 60.61% |
Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value.
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.
